tiprankstipranks
Trending News
More News >

PuraPharm Schedules Board Meeting to Approve 2024 Annual Results

Story Highlights
  • PuraPharm operates in the pharmaceutical industry, focusing on traditional Chinese medicine.
  • The board meeting will consider approving 2024 annual results and a potential dividend.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
PuraPharm Schedules Board Meeting to Approve 2024 Annual Results

PuraPharm Corp. Ltd. ( (HK:1498) ) just unveiled an update.

PuraPharm Corporation Limited has announced an upcoming board meeting scheduled for March 27, 2025. The meeting will focus on approving the annual results for the year ending December 31, 2024, and considering the payment of a final dividend, which could impact the company’s financial strategy and shareholder returns.

More about PuraPharm Corp. Ltd.

PuraPharm Corporation Limited is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. The company, along with its subsidiaries, is involved in the development and distribution of traditional Chinese medicine products.

YTD Price Performance: 1.82%

Average Trading Volume: 90,086

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$221.2M

See more insights into 1498 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App